At a glance
ClinicalIndex Comparison Record- ✓Type 2 diabetes diagnosed ≥90 days before screening
- ✓Stable daily dose of oral antidiabetic drug (OAD) and/or insulin ≥60 days before screening
- ✓HbA1c 7.5–10% (59–86 mmol/mol)
- ✓Semaglutide indicated per approved local label
- ✕Prior glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication
- ✕eGFR <30 mL/min/1.73 m²
- ✕Myocardial infarction, stroke, unstable angina, or transient ischemic attack within 180 days
- ✕NYHA Class IV heart failure
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Tolerability of Weekly Semaglutide 0.5 mg or 1.0 mg in Chilean Subjects With Type 2 Diabetes
In Brief
A Phase 4 clinical trial evaluating Semaglutide for Diabetes Mellitus, Type 2. Completed, enrolled 104 participants across 3 sites.
Detailed Summary
This study is testing the safety and tolerability of subcutaneous semaglutide in participants with type 2 diabetes (T2D) in Chile. Participants will get a once-weekly subcutaneous injection of semaglutide in doses decided by the study doctor's criteria, according to participant's personal needs. The study will last for about 24 weeks. Participants will have 4 clinic visits and 2 phone calls. Participants will have 3 laboratory tests during the study (blood and urine samples).
Study Details
Timeline
Interventions
Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.